Mindbeam sets generative AI models to task on drug design, hunting for better pain meds
Enterprise artificial intelligence infrastructure startup Mindbeam AI Inc. today published research showing how generative AI can aid in the discovery of safer pain-relief drugs.
The company used acetaminophen, one of the most widely used over-the-counter pain relievers worldwide, as a starting point.
Using a combination of generative AI, computational modeling and virtual screening, the Mindbeam evaluated 24 new drug candidates. The company targeted TRPV1, a receptor involved in pain signaling, best known for its interaction with capsaicin, the compound in peppers that causes the “burning” sensation and also signals heat and inflammation.
The company put the candidates through a series of efficacy and toxicity assessments. In the end, the team identified three lead compounds that demonstrated strong potential as future pain-relief therapies, and one finally emerged as particularly promising.
